Abeona Therapeutics (ABEO)

[wkpeters]

Access Initiates Phase I/II testing of Thiarabine

http://www.tradingmarkets.com/news/stock-alert/accp_access-initiates-phase-i/ii-blood-cancer-trial-1091279.html

Aug 05, 2010 (Datamonitor via COMTEX) --
Access Pharmaceuticals, a biopharmaceutical company, has initiated a Phase I/II dose-escalating study of its proprietary, anti-cancer drug, Thiarabine, a nucleoside analogue for patients with hematologic malignancies.

The primary objective of the study is to determine the maximum tolerated dose in two different dosing schedules with various leukemias and lymphomas and recommended Phase II dose, the company reported.

The clinical development program follows previously conducted Phase I and Phase II trials of Thiarabine in solid tumors, where myelosuppression, particularly lymphopenia was dose limiting.

David Nowotnik, senior vice president of R&D at Access, said: "The findings in preclinical and clinical studies to this point have given us a strong indicator that Thiarabine could be highly beneficial in treating patients with hematologic malignancies. The new Phase I/II trial at MD Anderson, a cancer center, is the next step in our comprehensive plan to build on the strong set of data and clinical results that have been generated to date on Thiarabine."